Literature DB >> 7772576

The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan.

H Ogawa1, M Sakuma, S Morioka, K Kitamura, Y Sasai, S Imamura, Y Inaba.   

Abstract

To evaluate the significance of the association of malignancy with autoimmune blistering diseases, we studied the incidence of internal malignancies in pemphigus and bullous pemphigoid based upon 496 cases of pemphigus and 1113 cases of bullous pemphigoid in Japan. Results showed that (1) an association between internal malignancies and pemphigus was observed in 25 out of 496 cases (5.0%), while that with bullous pemphigoid was seen in 64 out of 1113 cases (5.8%). Such association ratios were significantly higher than that of the controls aged over 70 years old (0.61%); (2) The average ages of pemphigus/bullous pemphigoid with malignancy were 64.7 and 69.2 years, respectively. The association ratio of malignancy with pemphigus increased by age, while that with pemphigoid was not correlated with aging; (3) Lung cancer was most common in pemphigus and gastric cancer in bullous pemphigoid; (4) There were no significant differences in the titers of circulating antibody, the presence or extent of mucous involvement or annular erythema between bullous pemphigoid patients with malignancy and without malignancy. Our results indicated that detailed examination for internal malignancy is essential for those patients with pemphigus or bullous pemphigoid.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772576     DOI: 10.1016/0923-1811(94)00371-k

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  21 in total

1.  A Monocentric Retrospective Observational Study of Comorbidities in Patients Affected by Autoimmune Bullous Diseases.

Authors:  Martina Ferranti; Giulia Gobbo; Giulia Tadiotto Cicogna; Mauro Alaibac
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Malignancies in pemphigus and pemphigoid diseases.

Authors:  Franziska Schulze; Kathrin Neumann; Andreas Recke; Detlef Zillikens; Roland Linder; Enno Schmidt
Journal:  J Invest Dermatol       Date:  2015-01-05       Impact factor: 8.551

Review 3.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 4.  Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management.

Authors:  Minhee Kim; Luca Borradori; Dédée F Murrell
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

5.  Dramatic resolution of bullous pemphigoid after surgery for gastric cancer: A case report.

Authors:  Keita Noguchi; Hideki Kawamura; Hiroyuki Ishizu; Kuniaki Okada
Journal:  Int J Surg Case Rep       Date:  2014-02-26

6.  Bullous pemphigoid in an elderly patient with myelodysplastic syndrome and refractory anemia coupled with excess of blast.

Authors:  Yin Yin Lee; Ping Chong Bee; Chew Kek Lee; Manimalar Naiker; Rokiah Ismail
Journal:  Ann Dermatol       Date:  2011-12-27       Impact factor: 1.444

Review 7.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

8.  Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis.

Authors:  T Krenacs; G Kiszner; E Stelkovics; P Balla; I Teleki; I Nemeth; E Varga; I Korom; T Barbai; V Plotar; J Timar; E Raso
Journal:  Histochem Cell Biol       Date:  2012-06-12       Impact factor: 4.304

9.  Coexistent Solid Malignancies in Pemphigus: A Population-Based Study.

Authors:  Khalaf Kridin; Shira Zelber-Sagi; Doron Comaneshter; Arnon D Cohen
Journal:  JAMA Dermatol       Date:  2018-04-01       Impact factor: 10.282

Review 10.  Pemphigus group: overview, epidemiology, mortality, and comorbidities.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-04       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.